Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$23.41 USD
+0.68 (2.99%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $23.47 +0.06 (0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCYC 23.41 +0.68(2.99%)
Will BCYC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCYC
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?
Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates
Other News for BCYC
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
Bicycle Therapeutics Announces Board Reshuffle and New Financial Agreement
Expert Ratings For Bicycle Therapeutics
Analysts Conflicted on These Healthcare Names: Tilray (TLRY), Hologic (HOLX) and Bicycle Therapeutics (BCYC)
Bicycle Therapeutics: Strong Buy on Breakthrough Preclinical Data, Clinical Progress, and Robust Financial Health